The role of anti(myco)bacterial interventions in the management of IBD: Is there evidence at all?

Digestive Diseases

Volumn 30, Issue 4, 2012, Pages 358-367

  Pineton De Chambrun, Guillaume P ^a,b,c   Torres, Joana ^e   Darfeuille Michaud, Arlette ^d   Colombel, Jean Frédéric ^a,b,c,e,f  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE LILLE   (France)

^d UNIVERSITÉ CLERMONT AUVERGNE   (France)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f Clin Maladies l'Appareil Digestif   (France)

Author keywords

Antibiotics; Crohn's disease; Ulcerative colitis

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CEFOPERAZONE; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; COTRIMOXAZOLE; DAPSONE; ETHAMBUTOL; FUSIDIC ACID; MEROPENEM; METRONIDAZOLE; ORNIDAZOLE; PLACEBO; RIFABUTIN; RIFAMPICIN; RIFAXIMIN; TETRACYCLINE; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; CANDIDA ALBICANS; CHLAMYDIA TRACHOMATIS; CROHN DISEASE; HUMAN; ILEITIS; LISTERIA; MYCOBACTERIUM PARATUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REMISSION; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; YERSINIA;

ANIMALS; ANTI-BACTERIAL AGENTS; COLITIS, ULCERATIVE; CROHN DISEASE; HEALTH PLANNING GUIDELINES; HUMANS; INFLAMMATORY BOWEL DISEASES; POUCHITIS;

EID: 84863968492     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000338126     Document Type: Article

References (95)

1. Xavier RJ, Podolsky DK: Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-434.
2. Glasser AL, Boudeau J, Barnich N, Perruchot MH, Colombel JF, Darfeuille-Michaud A: Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. Infect Immun 2001; 69: 5529-5537.
3. Thompson AI, Lees CW: Genetics of ulcerative colitis. Inflamm Bowel Dis 2011; 17: 831-848.
4. Gionchetti P, Rizzello F, Lammers KM, Morselli C, Tambasco R, Campieri M: Antimicrobials in the management of inflammatory bowel disease. Digestion 2006; 73(suppl 1): 77-85.
5. Isaacs KL, Sartor RB: Treatment of inflammatory bowel disease with antibiotics. Gastroenterol Clin North Am 2004; 33: 335-345.
6. Perencevich M, Burakoff R: Use of antibiotics in the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 651-664.
7. Sartor RB: Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126: 1620-1633.
8. Biancone L, Michetti P, Travis S, Escher JC, Moser G, Forbes A, et al: European Evidence-Based Consensus on the Management of Ulcerative Colitis: special situations. J Crohns Colitis 2008; 2: 63-92.
9. Dignass A, Van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel JF, et al: The Second European Evidence-Based Consensus on the Diagnosis and Management of Crohn's Disease: current management. J Crohns Colitis 2010; 4: 28-62.
10. Kornbluth A, Sachar DB: Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501-523; quiz 24.
11. Lichtenstein GR, Hanauer SB, Sandborn WJ: Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104: 465-483; quiz 4, 84.
12. Travis SP, Stange EF, Lemann M, Oresland T, Bemelman WA, Chowers Y, et al: European Evidence-Based Consensus on the Management of Ulcerative Colitis: current management. J Crohns Colitis 2008; 2: 24-62.
13. Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, et al: The Second European Evidence-Based Consensus on the Diagnosis and Management of Crohn's Disease: special situations. J Crohns Colitis 2010; 4: 63-101.
14. Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, et al: Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 661-673.
15. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P: Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114: 262-267.
16. Rutgeerts P, Goboes K, Peeters M, Hiele M, Penninckx F, Aerts R, et al: Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991; 338: 771-774.
17. Baumgart DC, Sandborn WJ: Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641-1657.
18. Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, et al: Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum. ISME J 2007; 1: 403-418.
19. Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, et al: High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004; 127: 412-421.
20. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR: Molecularphylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007; 104: 13780-13785.
21. Neut C, Bulois P, Desreumaux P, Membre JM, Lederman E, Gambiez L, et al: Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am J Gastroenterol 2002; 97: 939-946.
22. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, et al: Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122: 44-54.
23. Tamboli CP, Neut C, Desreumaux P, Colombel JF: Dysbiosis in inflammatory bowel disease. Gut 2004; 53: 1-4.
24. Pineton de Chambrun G, Colombel JF, Poulain D, Darfeuille-Michaud A: Pathogenic agents in inflammatory bowel diseases. Curr Opin Gastroenterol 2008; 24: 440-447.
25. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Buschenfelde KH: Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 102: 448-455.
26. Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J, Bjarnason I: Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996; 38: 365-375.
27. Podolsky DK: Inflammatory bowel disease. N Engl J Med 2002; 347: 417-429.
28. Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nunez G, et al: Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005; 307: 731-734.
29. Travassos LH, Carneiro LA, Ramjeet M, Hussey S, Kim YG, Magalhaes JG, et al: Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010; 11: 55-62.
30. Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaffeler E, Schlee M, et al: NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 2004; 53: 1658-1664.
31. Sartor RB: Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when. Curr Opin Gastroenterol 2003; 19: 358-365.
32. Bamias G, Marini M, Moskaluk CA, Odashima M, Ross WG, Rivera-Nieves J, et al: Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn's disease. J Immunol 2002; 169: 5308-5314.
33. Fiorucci S, Distrutti E, Mencarelli A, Barbanti M, Palazzini E, Morelli A: Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion 2002; 66: 246-256.
34. Hoentjen F, Harmsen HJ, Braat H, Torrice CD, Mann BA, Sartor RB, et al: Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin 10 gene deficient mice. Gut 2003; 52: 1721-1727.
35. Madsen KL, Doyle JS, Tavernini MM, Jewell LD, Rennie RP, Fedorak RN: Antibiotic therapy attenuates colitis in interleukin 10 genedeficient mice. Gastroenterology 2000; 118: 1094-1105.
36. Onderdonk AB, Hermos JA, Dzink JL, Bartlett JG: Protective effect of metronidazole in experimental ulcerative colitis. Gastroenterology 1978; 74: 521-526.
37. Rath HC, Schultz M, Freitag R, Dieleman LA, Li F, Linde HJ, et al: Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 2001; 69: 2277-2285.
38. Videla S, Vilaseca J, Guarner F, Salas A, Treserra F, Crespo E, et al: Role of intestinal microflora in chronic inflammation and ulceration of the rat colon. Gut 1994; 35: 1090-1097.
39. Yamada T, Deitch E, Specian RD, Perry MA, Sartor RB, Grisham MB: Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 1993; 17: 641-662.
40. Borgaonkar MR, MacIntosh DG, Fardy JM: A meta-analysis of antimycobacterial therapy for Crohn's disease. Am J Gastroenterol 2000; 95: 725-729.
41. Afdhal NH, Long A, Lennon J, Crowe J, O'Donoghue DP: Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo. Dig Dis Sci 1991; 36: 449-453.
42. Arnold GL, Beaves MR, Pryjdun VO, Mook WJ: Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis 2002; 8: 10-15.
43. Graham DY, Al-Assi MT, Robinson M: Prolonged remission in Crohn's disease following therapy for Mycobacterium paratuberculosis infection. Gastroenterology 1995; 108:A826.
44. Leiper K, Martin K, Ellis A, Watson AJ, Morris AI, Rhodes JM: Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. Aliment Pharmacol Ther 2008; 27: 1233-1239.
45. Lochs H, Prantera C, Gionchetti P, Danese S, Fogli MV, Grimaldi M: A new extended intestinal release formulation of rifaximin, 400 mg tablets, for the treatment of moderately active Crohn's disease. Gastroenterology 2011; 140(5 suppl 1):S-572.
46. Prantera C, Kohn A, Mangiarotti R, Andreoli A, Luzi C: Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 1994; 89: 513-518.
47. Prantera C, Lochs H, Campieri M, Scribano ML, Sturniolo GC, Castiglione F, et al: Antibiotic treatment of Crohn's disease: results of a multicentre, double-blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 2006; 23: 1117-1125.
48. Selby W, Pavli P, Crotty B, Florin T, Radford-Smith G, Gibson P, et al: Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 2007; 132: 2313-2319.
49. Steinhart AH, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K, et al: Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002; 123: 33-40.
50. Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, et al: Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991; 32: 1071-1075.
51. Bernstein LH, Frank MS, Brandt LJ, Boley SJ: Healing of perineal Crohn's disease with metronidazole. Gastroenterology 1980; 79: 357-365.
52. Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W: Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther 2003; 18: 1113-1120.
53. Ursing B, Kamme C: Metronidazole for Crohn's disease. Lancet 1975; 1: 775-777.
54. Maeda Y, Ng SC, Durdey P, Burt C, Torkington J, Rao PK, et al: Randomized clinical trial of metronidazole ointment versus placebo in perianal Crohn's disease. Br J Surg 2010; 97: 1340-1347.
55. Thia KT, Mahadevan U, Feagan BG, Wong C, Cockeram A, Bitton A, et al: Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebocontrolled pilot study. Inflamm Bowel Dis 2009; 15: 17-24.
56. West RL, van der Woude CJ, Hansen BE, Felt-Bersma RJ, van Tilburg AJ, Drapers JA, et al: Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2004; 20: 1329-1336.
57. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, et al: Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108: 1617-1621.
58. Rutgeerts P, Van Assche G, Vermeire S, D'Haens G, Baert F, Noman M, et al: Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005; 128: 856-861.
59. Doherty GA, Bennett GC, Cheifetz AS, Moss AC: Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn's disease. Aliment Pharmacol Ther 2010; 31: 802-809.
60. Burke DA, Axon AT, Clayden SA, Dixon MF, Johnston D, Lacey RW: The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 1990; 4: 123-129.
61. Chapman RW, Selby WS, Jewell DP: Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986; 27: 1210-1212.
62. Dickinson RJ, O'Connor HJ, Pinder I, Hamilton I, Johnston D, Axon AT: Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 1985; 26: 1380-1384.
63. Gilat T, Suissa A, Leichtman G, Delpre G, Pavlotzky M, Grossman A, et al: A comparative study of metronidazole and sulfasalazine in active, not severe, ulcerative colitis. An Israeli multicenter trial. J Clin Gastroenterol 1987; 9: 415-417.
64. Gionchetti P, Rizzello F, Ferrieri A, Venturi A, Brignola C, Ferretti M, et al: Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci 1999; 44: 1220-1221.
65. Mantzaris GJ, Archavlis E, Christoforidis P, Kourtessas D, Amberiadis P, Florakis N, et al: A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol 1997; 92: 454-456.
66. Mantzaris GJ, Hatzis A, Kontogiannis P, Triadaphyllou G: Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 1994; 89: 43-46.
67. Mantzaris GJ, Petraki K, Archavlis E, Amberiadis P, Kourtessas D, Christidou A, et al: A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 2001; 36: 971-974.
68. Ohkusa T, Kato K, Terao S, Chiba T, Mabe K, Murakami K, et al: Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol 2010; 105: 1820-1829.
69. Ohkusa T, Nomura T, Terai T, Miwa H, Kobayashi O, Hojo M, et al: Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol 2005; 40: 1334-1342.
70. Turunen UM, Farkkila MA, Hakala K, Seppala K, Sivonen A, Ogren M, et al: Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 1998; 115: 1072-1078.
71. Abdelrazeq AS, Kelly SM, Lund JN, Leveson SH: Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. Colorectal Dis 2005; 7: 182-186.
72. Gionchetti P, Rizzello F, Venturi A, Ugolini F, Rossi M, Brigidi P, et al: Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999; 13: 713-718.
73. Isaacs KL, Sandler RS, Abreu M, Picco MF, Hanauer SB, Bickston SJ, et al: Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2007; 13: 1250-1255.
74. Madden MV, McIntyre AS, Nicholls RJ: Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994; 39: 1193-1196.
75. McLaughlin SD, Clark SK, Tekkis PP, Ciclitira PJ, Nicholls RJ: An open study of maintenance antibiotic therapy for chronic antibiotic-dependent pouchitis: efficacy, complications and outcome. Colorectal Dis 2011; 13: 438-444.
76. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, et al: Four-week openlabel trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 2002; 16: 909-917.
77. Sandborn WJ: Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology 1994; 107: 1856-1860.
78. Sandborn WJ, Pardi DS: Clinical management of pouchitis. Gastroenterology 2004; 127: 1809-1814.
79. Shen B, Achkar JP, Lashner BA, Ormsby AH, Remzi FH, Brzezinski A, et al: A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001; 7: 301-305.
80. Shen B, Remzi FH, Lopez AR, Queener E: Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterol 2008; 8: 26.
81. Kyne L, Farrell RJ, Kelly CP: Clostridium difficile . Gastroenterol Clin North Am 2001; 30: 753-777.
82. Goodhand JR, Alazawi W, Rampton DS: Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 428-441.
83. Dial S, Kezouh A, Dascal A, Barkun A, Suissa S: Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ 2008; 179: 767-772.
84. Gaia E, Pais P, Salacone P, Morello C: Preliminary results obtained with cefoperazone plus corticosteroids in the treatment of active Crohn's disease. Inflamm Bowel Dis 2009; 15: 1123-1124.
85. Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, Egger M: Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. Clin Infect Dis 2010; 50: 473-480.
86. Shafran I, Kugler L, El-Zaatari FA, Naser SA, Sandoval J: Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease. Dig Liver Dis 2002; 34: 22-28.
87. McLaughlin SD, Clark SK, Shafi S, Petrovska L, Tekkis PP, Ciclitira PJ, et al: Fecal coliform testing to identify effective antibiotic therapies for patients with antibiotic-resistant pouchitis. Clin Gastroenterol Hepatol 2009; 7: 545-548.
88. Greenberg GR: Antibiotics should be used as first-line therapy for Crohn's disease. Inflamm Bowel Dis 2004; 10: 318-320.
89. Isaacs KL, Lewis JD, Sandborn WJ, Sands BE, Targan SR: State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis 2005; 11(suppl 1):S3-S12.
90. Boulos A, Rolain JM, Raoult D: Antibiotic susceptibility of Tropheryma whipplei in MRC5 cells. Antimicrob Agents Chemother 2004; 48: 747-752.
91. Fedorak RN, Madsen KL: Probiotics and prebiotics in gastrointestinal disorders. Curr Opin Gastroenterol 2004; 20: 146-155.
92. Fedorak RN, Madsen KL: Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 286-299.
93. Roberts CL, Keita AV, Duncan SH, O'Kennedy N, Soderholm JD, Rhodes JM, et al: Translocation of Crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers. Gut 2010; 59: 1331-1339.
94. Barnich N, Carvalho FA, Glasser AL, Darcha C, Jantscheff P, Allez M, et al: CEACAM6 acts as a receptor for adherent-invasive E. coli , supporting ileal mucosa colonization in Crohn disease. J Clin Invest 2007; 117: 1566-1574.
95. Carvalho FA, Barnich N, Sivignon A, Darcha C, Chan CH, Stanners CP, et al: Crohn's disease adherent-invasive Escherichia coli colonize and induce strong gut inflammation in transgenic mice expressing human CEACAM. J Exp Med 2009; 206: 2179-2189.